Stock Events

Stock Events

Applied Therapeutics

0

0

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious diseases, including genetic disorders, which overlaps with Applied Therapeutics' focus on rare diseases.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals competes in the space of rare diseases with its RNAi therapeutics, directly competing with Applied Therapeutics' approach to targeting rare metabolic diseases.

Biogen is involved in the discovery and development of therapies for serious diseases including rare genetic disorders, making it a competitor in the biopharmaceutical space targeting similar patient populations.

Biomarin Pharmaceutical

BioMarin Pharmaceutical specializes in enzyme replacement therapies and other drug development for rare genetic diseases, directly competing with Applied Therapeutics' focus areas.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is known for its work in biotechnology and developing treatments for a variety of diseases, including rare diseases, making it a competitor in the biopharmaceutical field.

Amgen focuses on human therapeutics, including treatments for serious illnesses that may overlap with Applied Therapeutics' target areas, making it a competitor.

Gilead Sciences

Gilead Sciences is a research-based biopharmaceutical company that develops drugs for serious diseases, including areas that may compete with Applied Therapeutics' focus on rare diseases.

Novo Nordisk is a global healthcare company with a focus on diabetes care and other serious chronic conditions, potentially competing in the metabolic disease space with Applied Therapeutics.

Pfizer is a large pharmaceutical company with a broad portfolio that includes treatments for rare diseases and other serious conditions, making it a competitor across various therapeutic areas.

About

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Show more...

CEO

Mr. John H. Johnson

Employees

35

Country

United States

ISIN

US03828A1016

WKN

000A2PHHB

Listings

0 Comments

Share your thoughts

FAQ

What is Applied Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Applied Therapeutics stocks are traded under the ticker 2UV.MU.

How many employees does Applied Therapeutics have?▼

As of September 04, 2026, the company has 35 employees.

In which sector is Applied Therapeutics located?▼

Applied Therapeutics operates in the Health & Wellness sector.

When did Applied Therapeutics complete a stock split?▼

Applied Therapeutics has not had any recent stock splits.

Where is Applied Therapeutics headquartered?▼

Applied Therapeutics is headquartered in New York, United States.